

FLORIDA SOCIETY OF CLINICAL ONCOLOGY FAX BLAST – June 5, 2008

MESSAGE FROM FLASCO PRESIDENT: Robert Cassell, MD

FLASCO extends a special thanks to **GENZYME** for becoming a Bronze Member for 2008.

PROGRAM COMMITTEE: Rogerio Lilenbaum, MD, Chairman

FLASCO is providing the following educational opportunities in June: “Updates in the Treatment of Breast Cancer.” The Speaker will be John Crown, MD. These dinner meetings are being sponsored by Sanofi-Aventis Oncology. A Flyer is included with this fax blast. Target Audience: Medical Oncologists, Radiation Oncologists, Breast Cancer Surgeons, Nurse Practitioners, Physician Assistants, and Oncology Nurses

Monday, June 16, 2008

The Palm Restaurant - Tampa

Wednesday, June 18, 2008

Matthew’s Restaurant – Jacksonville

CLINICAL PRACTICE COMMITTEE: Tom Gaddis, MD, Chairman

Guidance on imaging code 77014. The imaging code 77014 is a component of 77295 and can't be billed on the same day under any circumstance (no modifiers can be used). This is an NCCI edit that your billing system should catch before bills go out.

DRUG/INDUSTRY UPDATES:

Trastuzumab (Herceptin) Is Approved for 2 New Regimens - Genentech

The Food and Drug Administration has approved two new uses for trastuzumab with hormone therapy in HER2 overexpressing, node-positive or high-risk node-negative breast cancer. The new approvals are for use of trastuzumab as part of a treatment regimen containing doxorubicin, cyclophosphamide, and docetaxel and as part of a regimen that includes docetaxel and carboplati

FCSO UPDATES:

2008 Medicare Physician Fee Schedule Database Indicators - Last Modified: 6/2/2008

Definitions of indicators used for each procedure code (and modifier, where applicable) on the Medicare physician fee schedule database (MPFSDB). Use this in conjunction with the MPFS - National Searchable Database on the CMS Web site. [CR 5774] http://www.floridamedicare.com/Part_B/Headlines/118368.asp

Florida Medicare Mail Directory - Last Modified: 5/30/2008

Important addresses for contacting Medicare Part A and Part B. Also includes the address for direct feedback to CMS on FCSO's performance as a contractor - <http://www.floridamedicare.com/header/Contact/108271.asp>

July Update to the 2008 Medicare Physician Fee Schedule Database – Part A & B- Last Modified: 6/3/2008

This change provides update information for physicians and providers who submit services rendered to Medicare beneficiaries that are paid based on the Medicare Physician Fee Schedule Database (MPFSDB). [MM6087] http://www.floridamedicare.com/Part_A/Billing_and_Coverage/128281.asp
http://www.floridamedicare.com/Part_B/Headlines/128281.asp

Date of Service for Clinical Laboratory and Pathology Specimens – Part A & B - Last Modified: 6/3/2008

CR 6018 alerts providers that the CMS revised the date of service policy for clinical laboratory tests and added the technical component of physician pathology service effective January 1, 2009. [MM6018] http://www.floridamedicare.com/Part_A/Billing_and_Coverage/128268.asp
http://www.floridamedicare.com/Part_B/Headlines/128276.asp

Average Sales Price Updates – Part A & B- Last Modified: 6/3/2008

This article is informational to advise providers that the information is now in the Medicare manual. The payment limits included in the revised payment files supersede the payment limits for these codes in any earlier publication. [MM5798]

[http://www.floridamedicare.com/Part A/Billing and Coverage/128267.asp](http://www.floridamedicare.com/Part_A/Billing_and_Coverage/128267.asp)

[http://www.floridamedicare.com/Part B/Headlines/128267.asp](http://www.floridamedicare.com/Part_B/Headlines/128267.asp)

CMS UPDATES:

MEDLEARN MATTERS

New:

MM6018 – Date of Service (DOS) for Clinical Laboratory and Pathology Specimens

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6018.pdf>

MM5798 – Average Sales Price (ASP) Updates

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5798.pdf>

SE0815 – Reminder that Exceptions to Therapy Caps are Restricted as of July 1, 2008

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/SE0815.pdf>

MM6045 – Quarterly Update to Correct Coding Initiative (CCI) Edits, Version 14.2, Effective July 1, 2008

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6045.pdf>

Rescinded:

MM5890 – Additional Information on Reporting a National Provider Identifier (NPI) for Ordering/Referring and Attending/Operating/Other/Service facility for Medicare Claims

ACCC UPDATES – Jeffrey Bubis, DO, FLASCO Liaison to ACCC

Oncology practices: Survey on Off-Label Use to Arrive June 3

ACCC along with Covance Market Access Services, Inc., is conducting research about oncology practices' use of off-label anticancer therapies. Specifically, we'll be looking at the role of off-label use of anticancer therapies in patient care, the evidence that oncologists use when prescribing anticancer therapies off-label, and the impact of public and private payers' coverage and reimbursement policies on physician prescribing and treatment patterns and patient access to anticancer therapies. The survey will be done on behalf of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Industry Organization (BIO).

June 3, ACCC began distributing an on-line survey to ACCC's physician office-based members on off-label use of anticancer therapies. This survey will be sent from the email address ACCCsurvey@covance.com. It is anticipated that the survey will take oncology practices approximately 15 minutes to complete.

This is a crucial time for drug compendia and off-label payer policy changes, so we hope that you will take the time to participate in this on-line survey. Thank you in advance for your participation in this research.

UNITED HEALTHCARE:

The United Healthcare Network Bulletin, Volume 25, May 2008, may be found at:

<http://p.p0.com/YesConnect/HtmlMessagePreview?a=WhcPuSoa6tmPLuYgiK7g&msgVersion=web>

FMA UPDATE:

We are excited to report that SB 2598 (the PRN Sovereign Immunity Bill) was approved by Governor Crist on May 28th. This legislation was a top priority for the FMA this legislative session. **FLASCO CONGRATULATES THE FMA ON THIS SUCCESSFUL ENDEAVOR.**

EDUCATIONAL OPPORTUNITIES:

JOIN A LIVE, INTERACTIVE WEBCAST: - Nexavar in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC)

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals Inc. welcome your participation in a live, online event. This is a unique, interactive opportunity to learn more about exciting developments in the treatment of patients with unresectable HCC. This educational opportunity is available commencing June 17, 2008 – through August 13, 2008.

LIVE AND INTERACTIVE WEB-BASED PRESENTATION

- 30-minute presentation streams live directly from the specialist to your office
 - View the presentation from your computer, or have a group presentation arranged for you
- 15-minute live question-and-answer session
 - Submit questions directly to the specialist from your computer

EDUCATIONAL OBJECTIVES

- Learn about the incidence, prevalence, and risk factors for HCC
- Discuss the Sorafenib HCC Assessment Randomized Protocol (SHARP) study design
- Review the final SHARP study data for Nexavar—the first and only systemic treatment approved for patients with unresectable HCC

To register for this promotional event, contact your Bayer or Onyx Oncology Specialist or log on to <http://www.pharmethod.com/bayeronyx/register> and follow the instructions on the link. Please feel free to direct any questions to the Bayer/Onyx PharmaCAST Program Manager at **1-866-606-0768**.

ImClone Systems Incorporated

Web based reimbursement updates available.

1. "2008 Washington Update" authored by Dr. Joseph Bailes, M.D.
2. "2008 Reimbursement and Coding Changes" authored by Bobbi Buell

If you are interested in having an ImClone representative visit your office and present one or both of these programs, please contact Bob Bexley at Bob.Bexley@imclone.com or call 770-331-4453.

DISCLAIMER: FLASCO has not reviewed these programs and “any views presented are not the views of FLASCO”

CORPORATE MEMBERSHIP/SPONSORSHIP: (January 1 – December 31, 2008)

FLASCO Members extends a big thanks to all of our 2008 Corporate Members/Sponsors

PLATINUM

Astra Zeneca
Bayer/Onyx
Cephalon Oncology
Eli Lilly
Oncology Supply/ION
Sanofi-Aventis
OPR
Pharmion
AMGEN
Genentech
Abraxis Oncology.
Ortho Biotech

GOLD

Celgene
Genomic Health
Novartis
Pfizer
Roche
GlaxoSmithKline
Bristol Myers Squibb
Wyeth

SILVER

MGI Pharma
US Oncology
ImClone Systems
OSI Pharmaceuticals
Millennium Pharmaceuticals, Inc.

BRONZE

Boehringer Ingelheim
Pharmaceuticals, Inc.
Alexion
Genzyme

FLASCO EVENTS:

June 16, 2008 – Updates in the Treatment of Breast Cancer – The Palm Restaurant, Tampa – 6:30 – 9:30pm

June 18, 2008 – Updates in the Treatment of Breast Cancer – Matthew’s Restaurant, Jacksonville – 6:00-8:00 pm

August 8-9, 2008 – FLASCO Executive Committee Retreat – Marriott World Center Hotel - Orlando

November 7-8, 2008 – FLASCO Fall Meeting – Tampa Airport Marriott Hotel

January 17-18, 2009 – Clinical Breakthroughs & Challenges in Hematologic Malignancies – Grand Floridian Resort – Lake Buena Vista

February 27 & 28, 2009 – FLASCO Spring Meeting – Marriott Sawgrass – Jacksonville

March 20, 2009 – Statewide PA & NP Conference, Moffitt Cancer Center - Tampa

FLASCO Contact Information: Dorothy Green Phillips, Executive Director -3709W. Jetton Ave., Tampa, Florida 33629 - Tel: 800.444.1410, Ext. 4410 - Cell Phone: 813.294.2620 - Fax: 813.349-4410 or 813.349.4472
Email: Dorothy.Green@cancer.org

OTHER EVENTS:

May 30 – June 4, 2008 – ASCO Annual Meeting - Chicago

September 17-20, 2008 – ACCC 25th National Oncology Economic Conference – San Francisco, California

September 19-20, 2008 - Annual ASCO/ASH/SGO Meeting of the Hematology/Oncology CAC Network


September 25-28, 2008 - Oncology Congress - the Hilton San Francisco

December 6-9, 2008 – ASH Annual meeting – San Francisco

February 26-28, 2009 – ASCO - GU Symposium, Orlando World Center Marriott

March 20, 2009 – Statewide PA/NP Conference – Moffitt Cancer Center

March 22-24.2009 - 2009 AOHA Assembly Conference – Los Angeles, California



YOU ARE INVITED

The Florida Society of Clinical Oncology (FLASCO) cordially invites you to attend:




“Updates in the Treatment of Breast Cancer”

Presented by: John Crown M.D.

Speaker – John Crown, MD is a consultant medical oncologist at St. Vincent's Hospital, St. Luke's Hospital and St. Anne's Hospital, all of which are located in Dublin. He is chairman of the Department of Medical Oncology at St. Luke's and is board certified in internal medicine and the oncology subspecialty.

Dr. Crown is founder and chairman of the Irish Clinical Oncology Research Group and a founding member of the Irish Society of Medical Oncology. Additionally, he serves as co-chairman of both the Anglo-Celtic Study Group and the Breast European Adjuvant Studies team and as chairman of the European Breast Dose Intensity Study Group.

He was an intern at Mater Hospital in Dublin and then was in the pathology program at University College, Dublin. After appointments at Federated Dublin Voluntary Hospitals and Guy's Hospital in London, Dr. Crown was a registrar in hematology and oncology at St. James's Hospital. He then completed a fellowship in neoplastic disease at Mount Sinai in New York and a fellowship in hematology and oncology at Memorial Sloan-Kettering Cancer Center.



<p>Monday, June 16, 2008 The Palm Restaurant 205 Westshore Drive Tampa, FL 33607 813-849-7256 6:30 p.m. – 9:30 p.m. RSVP: Lisa Tawil Lisa.Tawil@sanofi-aventis.com Cell : 813-416-8109 or Vivian Curran Vivian Curran@sanofi-aventis.com Cell : 727-251-2726</p>	<p>Wednesday, June 18, 2008 Matthew's Restaurant 2107 Hendriks Avenue Jacksonville, FL 32207 904-396-9922 6:00 PM – 8:00 PM RSVP: Richard Rabren Richard.rabren@sanofi-aventis.com Cell: 904-566-1024</p>
<p>Target Audience: Medical Oncologists Radiation Oncologists Breast Cancer Surgeons Nurse Practitioners Oncology Nurses Physician Assistants</p>	<p>Program Sponsored by Sanofi-Aventis Oncology</p>